The private equity firms have agreed to pay more to Stada minority stockholders in a settlement that could add an extra €180-190m to their initial €5.4bn purchase price.
The Stada Arzneimittel AG takeover story has taken another turn after new owners Bain Capital and Cinven agreed to pay more to minority shareholders in order to gain full control of the German generic drug maker.
The private equity firms have given in to demands issued at the end of last week by prominent activist hedge fund Elliott Management which said it wanted at least €74.40 per share to guarantee its support of Bain and Cinven's acquisition of Stada
The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
An ‘historic economic prosperity deal’ does not include the sector.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
